William Blair Reports 5.2% Of GeneDx Shares, With No Aim To Influence Control
The investment manager reported 1,560,247 shares, with sole voting authority over 1,418,435.
William Blair Investment Management reported a 5.2% stake in GeneDx Holdings, which provides genetic testing to help clinicians diagnose genetic diseases, in a passive ownership disclosure filed Friday. The manager said it holds the shares for ordinary business purposes, not to change or influence control of the company.
Ownership And Voting Authority
The position totaled 1,560,247 common shares. The disclosure identifies September 30, 2026, as the reporting event date; Friday is the filing date.
William Blair reported sole voting authority over 1,418,435 shares and sole authority to dispose of 1,560,247 shares. Shared voting and disposal authority were both zero.
The ownership percentage is measured under SEC beneficial-ownership rules. William Blair also certified that the position was not acquired or held as part of a transaction aimed at changing or influencing GeneDx’s control.
Genetic Tests For Rare Disorders
GeneDx’s diagnostic work focuses particularly on rare disorders in children. Its ExomeDx test examines protein-coding DNA, while GenomeDx examines the whole genome, looking for genetic changes that may explain disease.
Diagnostic test reports generated substantially all of GeneDx’s revenue for the year ended December 31, 2025, according to its annual report. Payments come from insurers and other third-party payors, patients, business clients and healthcare partners.
